MedTrace Logo

Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)

NCT01136278 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2013-01-25

No results posted yet for this study

Summary

The purpose of this study is to determinate the effect of a pre-treatment with centrally acting alpha2-receptor agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). The investigators hypothesize that clonidine will attenuate the subjective and cardiovascular response to MDMA.

Conditions

  • Mood Disorder
  • Substance-Related Disorders
  • Amphetamine-Related Disorders

Interventions

DRUG

3,4-Methylenedioxymethamphetamine

125 mg, single dose

DRUG

Clonidine

150 μg per os

DRUG

placebo

capsules identical to MDMA or clonidine

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, MD · Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136278 on ClinicalTrials.gov